Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Peculiarities of breast cancer incidence rate in urban population and implementation of screening programs in health care system.

Zhero SV, Hotko YS, Tsyhyka DY, Ihnatko VY, Pohorelova NY.

Wiad Lek. 2016;69(1 Pt 2):61-3.

PMID:
27164278
2.

Male breast cancer: clinical presentation, diagnosis, treatment.

Hotko YS.

Exp Oncol. 2013 Dec;35(4):303-10. Review.

PMID:
24382442
3.

Receptor status of tumor as prognostic factor in patients with bilateral breast cancer.

Tsyhyka DY, Hotko YS, Devinyak OT.

Exp Oncol. 2013 Dec;35(4):291-4.

PMID:
24382440
4.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group.

N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.

5.

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group.

Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23.

6.

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW.

J Thorac Oncol. 2008 Jul;3(7):728-34. doi: 10.1097/JTO.0b013e31817c6b68.

Supplemental Content

Loading ...
Support Center